This post-AAD interview with Chovatiya covered takeaways regarding recent data on upadacitinib for vitiligo, tapinarof for eczema, and lutikizumab for hidradenitis suppurativa.
Kimball discusses her team’s new late-breaking data regarding the safety and effectiveness of lutikizumab in treating the symptoms of moderate-to-severe HS in adult non-responders to anti-TNF therapy.
In this segment of Porter’s interview, she delves further into the phase 2 findings on lutikizumab and discusses any adverse events and future research.
In this interview, Porter describes some new and encouraging phase 2 data on lutikizumab treatment for patients with HS who had failed anti-TNF therapy.